Inherent Biosciences, a Salt Lake City, UT-based company involved in commercializing a diagnostic in the emerging biotech field of epigenetics, raised a Series A funding of undisclosed amount.
The round was led by Propel Bio Partners with participation from numerous stakeholders from patients to physicians and reproductive healthcare executives including Portfolia’s FemTech II Fund as well as Alliance of Angels Innovation Fund.
The company intends to use the funds to expand its pipeline, scale commercial operations and generate the further seminal data necessary to add SpermQT to the standard of care.
Co-founded by Kristin Brogaard, Chief Scientific Officer; and Andy Olson, Chief Executive Officer, Inherent provides an epigenetic platform that detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics.
The company’s team of epigenetic technology innovators is made up of Dr. Larry Lipshultz, Professor of Urology and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine at Baylor College of Medicine; Dr. James Smith, Director of the Male Reproductive Health Center at UCSF; and Dr. Jim Hotaling, Director of the University of Utah Men’s Health program and current President of the Society for the Study of Male Reproduction, the premier society in the field.
FinSMEs
08/09/2022